| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Lumisterol targets the vitamin D receptor (VDR) pathway, although with lower affinity compared to 1alpha,25-dihydroxyvitamin D3. It serves as a photoprotective agent shielding against UVB-induced DNA damage and exhibits anti-proliferative activities. The compound may also interact with other steroid hormone receptors and influence gene expression related to cell growth, differentiation, and apoptosis.
|
|---|---|
| ln Vitro |
In vitro, Lumisterol has been shown to have anti-proliferative activities against various cancer cell lines. It acts as a photoprotective agent, protecting cells from UVB-induced DNA damage. The compound has demonstrated effects on cell cycle regulation and may induce differentiation in certain cell types. As a vitamin D-related compound, it may also influence calcium homeostasis and immune function in cell-based assays.
|
| ln Vivo |
In vivo, Lumisterol is a naturally occurring steroid compound found in human skin. It is produced from 7-dehydrocholesterol via a series of photochemical reactions during UVB exposure. The compound contributes to the overall photoprotective response of the skin, helping to shield against UVB-induced DNA damage. It may have systemic effects on bone and immune function, although its potency is much lower than active vitamin D.
|
| Enzyme Assay |
Lumisterol can be used in non-cellular receptor binding assays. The compound is dissolved in ethanol or DMSO to prepare a stock solution, then diluted into assay buffer (e.g., 10 mM Tris-HCl, pH 7.4). Vitamin D receptor (VDR) binding assays are performed using recombinant VDR protein, radiolabeled [3H]1alpha,25-dihydroxyvitamin D3, and varying concentrations of Lumisterol. After incubation at 4degC for 16-24 hours, bound and free radioligands are separated by charcoal-dextran precipitation or by using hydroxyapatite. IC50 values are calculated.
|
| Cell Assay |
For in vitro cellular experiments, cancer cell lines (e.g., keratinocytes, melanoma cells, breast cancer cells) are cultured in standard medium. Cells are treated with Lumisterol at concentrations ranging from 10 nM to 10 uM for 24-72 hours. Cell proliferation is assessed by MTT assay. DNA damage protection is evaluated by treating cells with UVB radiation in the presence or absence of Lumisterol and measuring cyclobutane pyrimidine dimers (CPDs) by ELISA or immunofluorescence. Cell cycle analysis is performed by flow cytometry.
|
| Animal Protocol |
For in vivo animal studies, Lumisterol can be administered to rodents via intraperitoneal injection or topical application to the skin. For UV protection studies, mice are treated with Lumisterol topically before UVB exposure. Skin samples are collected to measure DNA damage (CPDs) by immunohistochemistry. Blood samples may be collected for vitamin D metabolite analysis. For cancer studies, tumor-bearing mice may be treated with Lumisterol to assess anti-proliferative effects in vivo.
|
| ADME/Pharmacokinetics |
Lumisterol is an endogenous steroid and its PK properties are not well characterized. As a lipophilic compound (logP ∼7-8), it is expected to have high plasma protein binding (∼99%), a large volume of distribution, and a long half-life (days to weeks) if systemically absorbed. Topical application likely results in high skin concentrations with minimal systemic absorption. The compound is likely metabolized by cytochrome P450 enzymes (CYP27A1, CYP27B1) to more polar metabolites.
|
| Toxicity/Toxicokinetics |
Lumisterol is an endogenous steroid with low toxicity at physiological concentrations. Topical application for UV protection is generally considered safe. No acute toxicity data is available for Lumisterol as a research chemical. As a steroid, standard laboratory safety precautions for handling organic compounds are recommended. Not intended for human consumption. Avoid prolonged UV exposure if handling under UV light.
|
| References | |
| Additional Infomation |
A steroid compound found in fungi. Ultraviolet radiation can lead to the formation of ergocalciferol (vitamin D2).
Lumisterol is not a drug but a research-use endogenous metabolite. It has no approved therapeutic status. It is used in research to study vitamin D photochemistry, skin photoprotection, and UVB-induced DNA damage. Lumisterol is also used as an analytical standard in vitamin D metabolite profiling and in studies of steroid photoisomerization pathways. The compound has potential applications in photoprotective cosmetics and in studying the non-calcemic actions of vitamin D-related steroids. |
| Molecular Formula |
C28H44O
|
|---|---|
| Molecular Weight |
396.65
|
| Exact Mass |
396.339
|
| CAS # |
474-69-1
|
| Related CAS # |
Ergosterol;57-87-4
|
| PubChem CID |
6436872
|
| Appearance |
White to off-white solid powder
|
| Density |
1g/cm3
|
| Boiling Point |
501.5ºC at 760mmHg
|
| Melting Point |
118ºC
|
| Flash Point |
216.3ºC
|
| Vapour Pressure |
3.7E-12mmHg at 25°C
|
| Index of Refraction |
1.542
|
| LogP |
7.33
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
29
|
| Complexity |
712
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@@H]3C2=CC=C4[C@]3(CC[C@@H](C4)O)C)C
|
| InChi Key |
DNVPQKQSNYMLRS-YAPGYIAOSA-N
|
| InChi Code |
InChI=1S/C28H44O/c1-18(2)19(3)7-8-20(4)24-11-12-25-23-10-9-21-17-22(29)13-15-27(21,5)26(23)14-16-28(24,25)6/h7-10,18-20,22,24-26,29H,11-17H2,1-6H3/b8-7+/t19-,20+,22-,24+,25-,26+,27+,28+/m0/s1
|
| Chemical Name |
(3S,9R,10S,13R,14R,17R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (252.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5211 mL | 12.6056 mL | 25.2111 mL | |
| 5 mM | 0.5042 mL | 2.5211 mL | 5.0422 mL | |
| 10 mM | 0.2521 mL | 1.2606 mL | 2.5211 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
